A Phase I, Double-blind, Dose-ranging, Randomised, Placebo-controlled Trial to Study the Safety and Immunogenicity of a DNA-based Vaccine Against COVID-19 (COVIGEN) in Healthy Participants Aged 18 to 75 Years Old
Latest Information Update: 01 Nov 2023
At a glance
- Drugs Coronavirus vaccine-BioNet Asia (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms COVALIA
Most Recent Events
- 27 Oct 2023 Status changed from active, no longer recruiting to completed.
- 17 Nov 2022 Planned End Date changed from 30 Jun 2023 to 30 Jul 2023.
- 17 Nov 2022 Status changed from recruiting to active, no longer recruiting.